Factors Affecting Mortality of Sepsis Patients in General Hospital Dr. M. Djamil Padang
(1) Andalas University, Padang, West Sumatera, Indonesia
(2) RSUP Dr. M. Djamil Padang, Padang, West Sumatera, Indonesia
(*) Corresponding Author
Abstract
Background:
The high sepsis mortality rate is a significant problem that must be managed properly and comprehensively. Studies showed 30% mortality due to sepsis, 50% for severe sepsis, and 80% for sepsis shock. Data in Indonesia showed that 30.29% of sepsis patients were admitted, and 11.56% to 49% died. Vitamin D deficiency is associated with an increased risk of infection in sepsis.
Objective:
This study aims to determine the factors that play a role in the death of sepsis patients.
Methods:
This study used a cross-sectional analytic design. Data were tak-en from 42 patients who died from sepsis in the Intensive care unit of Dr. M. Djamil Padang Hospital from July 2022 to Sep-tember 2022. Patients were previously checked for vitamin D levels—data analysis using the Man Whitney test.
Results:
The average age of sepsis patients is 56 years old, female (59.9%), vitamin D deficiency (82.5%), obesity (64.3%), most comorbid with chronic kidney injury (CKD) (16.7%). Sepsis pa-tients who died of vitamin D deficiency had a mean Hb of 11.5 g/dl; leukocytosis (14.490/mm3), thrombocytopenia (225.000/mm3), hypoalbumin (2.4 g/dl) and high risk to sepsis based on procalcitonin levels (15.47 ng/ml). There was no sta-tistically significant relationship to the laboratory results (pValue>0.05).
Conclusion:
Vitamin D deficiency, female, obesity, CKD, thrombocytopenia, and hypoalbumin increase the mortality risk of sepsis patients in the intensive care Unit. The importance of recognizing demo-graphic and laboratory risk factors helps clinicians in preventing sepsis mortality.
Keywords
Full Text:
PDFReferences
Charles A, Dewayani BM, Sahiratmadja E, Winarno GNA, Susanto H. Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. Universa Med. 2016;35(3):165.
Shafiq M, Venkateshiah S. Hematologic abnormalities associated with lung carcinoma. Respir Care. 2011;56(4):523–6.
Yuliandra Y, Nasif H, Ermayanti S, Sulistyowati L, Juwita DA. Hematologic Toxicities of Chemotherapy in Lung Cancer Patients: A Retrospective Study in Dr. M. Djamil Hospital Padang, Indonesia. Indones J Clin Pharm. 2019;8(2):129–31.
Grandgirard J, Poinsot D, Krespi L, Nénon JP, Cortesero AM. Costs of secondary parasitism in the facultative hyperparasitoid Pachycrepoideus dubius: Does host size matter? Entomol Exp Appl. 2002;103(3):239–48.
Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination. Cancer. 2005;103(3):569–75.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, et al. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer. 2011;105(3):360–5.
Shukla P, Singh R. Potential pharmacological interventions against hematotoxicity: An overview. Expert Rev Hematol. 2015;8(4):505–14.
Muñoz-Langa J, De Castro J, Gascó P, Sanchez A, Esteban E, Gasent JM, et al. Chemotherapy-associated anemia in patients with lung cancer: An epidemiological, retrospective and multicenter study. Futur Oncol. 2015;11(11):1665–74.
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282–94.
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015;26(10):1054–60.
Chabner BA, Amrein PC, Druker B. Chemotherapy of Neoplastic Diseases. In: Goodman and Gilman ’s The Pharmacological Basis of Therapeutics New York: The McGraw-Hill Companies; 2011:1854–921.
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and Chemotherapy-Induced Anemia. J Natl Compr Cancer Netw. 2012;10(5):628–53.
Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Lung Cancer: Guidelines for Diagnosis & Management in Indonesia. Perhimpunan Dokter Paru Indonesia. 2018:49–50.
Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021;14(3):1–7.
Hoffbrand A, Moss P PJ. Essential Haematology. 5th ed. In: Victoria: Blackwell Publishing. 2006:115–89.
Usami E, Kimura M, Iwai M, Takenaka S, Teramachi H, Yoshimura T. Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mol Clin Oncol. 2016:591–6.
Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–14.
Anderson PO, Knoben JE, Troutman WG. Handbook of clinical drug data. 10th edition, McGraw-Hill, San Diego, CA. 2002:115–89.
Syahruddin E MN, Hudoyo A. Efficacy and toxicity chemotherapy with cisplatin + etoposide regimen in advanced stage non-small cell lung cancer. J Respir Indo. 2012;5:25–35.
Kurtin S. Myeloid Toxicity of Cancer Treatment. J Adv Pr Oncol. 2012:209–24.
De Silva E, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis. Chem Biol Interact. 2018;284:1–11.
Febriani A, Rahmawati Y. Efek Samping Hematologi Akibat Kemoterapi dan Tatalaksananya. J Respirasi. 2019;5(1):22–5.
Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. Int J Clin Transfus Med. 2018:21–31.
Anderson W. Guidelines for the management of chemotherapy and systemic anticancer therapy induced toxicities within primary care. Northen Cancer Alliace. 2018:3–21.
Article Metrics
Abstract view : 514 timesPDF - 142 times
DOI: https://doi.org/10.26714/magnamed.11.2.2024.114-121
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
MAGNA MEDIKA by APKKM is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Attention:
- We invite authors to submit manuscripts to our journal through official announcements on the journal's website, communication through associations, and personal communication with authors who have expertise in accordance with the objectives and scope of our journal.
- We do not offer fast publication, fast reviews, or acceptance guarantees.
![一般社団法人全国医学部国際交流協議会[J-MICA (Japanese Medical University International Collaborative Assembly)]](http://kokusaikouryu.net/img/banner01.png)






